Solasia Pharma KK (STU:9SO) Total Operating Expense: €3.22 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9SO Solasia Pharma KK STU:9SO
53 GF Score
Price €0.12
GF Value €0.01
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Solasia Pharma KK Total Operating Expense?

Solasia Pharma KK STU:9SO +4.31% 53 Total Operating Expense is €3.22 Mil as of Mar. 2026. GuruFocus rates STU:9SO with a GF Score™ of 53/100 and a GF Value™ of €0.01 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Solasia Pharma KK's Total Operating Expense for the three months ended in Mar. 2026 was €1.69 Mil. Solasia Pharma KK's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €3.22 Mil.

Solasia Pharma KK Total Operating Expense Related Terms

Solasia Pharma KK Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Solasia Pharma KK's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solasia Pharma KK Total Operating Expense Chart

Solasia Pharma KK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.71 21.92 9.40 13.26 5.85

Solasia Pharma KK Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.87 1.53 0.00 0.00 1.69
STU:9SO
53GF Score
Solasia Pharma KK STU:9SO
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solasia Pharma KK Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €3.22 Mil mean?
Solasia Pharma KK (STU:9SO) has a Total Operating Expense of €3.22 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Solasia Pharma KK and its competitors.
Is Solasia Pharma KK's Total Operating Expense too high?
Solasia Pharma KK's current Total Operating Expense is €3.22 Mil. Overall, Solasia Pharma KK has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Solasia Pharma KK's Total Operating Expense compare to ZTS and UTHR?
Solasia Pharma KK's Total Operating Expense of €3.22 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Drug Manufacturers company?
A good Total Operating Expense depends on the Drug Manufacturers industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Solasia Pharma KK and its competitors. Solasia Pharma KK's current Total Operating Expense is €3.22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solasia Pharma KK stock overvalued right now?
Based on GuruFocus' analysis, Solasia Pharma KK (STU:9SO) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.01, compared to a current price of €0.12 — trading 1110% above its estimated fair value. The current Total Operating Expense is €3.22 Mil. Solasia Pharma KK's overall GF Score™ is 53/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Solasia Pharma KK (STU:9SO), the current Total Operating Expense is €3.22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solasia Pharma KK (STU:9SO) Overvalued in 2026?

Based on GuruFocus' analysis, Solasia Pharma KK stock appears to be overvalued. The current stock price of €0.12 is trading 1110% above its estimated GF Value™ of €0.01. GuruFocus considers Solasia Pharma KK to be Significantly Overvalued.

Key valuation signals for STU:9SO:

  • Total Operating Expense: €3.22 Mil
  • GF Value™: €0.01 vs. price of €0.12 (1110% above fair value)
  • GF Score™: 53/100 with 6 warning signs

No single metric tells the full story. See the STU:9SO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Solasia Pharma KK Business Description

Other Exchanges 4597:Japan
Address 2-1-1 Shiba Park, 4th Floor, Sumitomo Real Estate Shiba Park Tower, Minato-ku, Tokyo, JPN, 105-0011
Solasia Pharma KK develops and distributes pharmaceuticals and medical devices relating to malignant tumors.
53GF Score

Get the complete analysis for STU:9SO

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.12
Price
€0.01
GF Value